AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Protocol: 
AAAR4300
Phase: 
III

AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

This partially randomized phase III trial studies how well active surveillance,
bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult
patients with germ cell tumors. Active surveillance may help doctors to monitor
subjects with low risk germ cell tumors after their tumor is removed. Drugs used in
chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading.

Are you Eligible? (Inclusion Criteria)

-Subjects may be up to 49 years of age at the time of study entry.
-Patients must have been diagnosed with a primary extracranial germ cell tumor.
-Subjects must be considered low risk or standard risk to participate.
-Patients must also meet all eligibility criteria as outlined in the study protocol.